Neogenomics (NEO) Capital Expenditures (2010 - 2026)

Neogenomics (NEO) has 17 years of Capital Expenditures data on file, last reported at $8.2 million in Q2 2026.

• Quarterly Capital Expenditures rose 29.99% year-over-year to $8.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $29.4 million (down 11.49% YoY) and the FY2025 annual result came in at $27.0 million, down 34.22% from the prior year.
• Capital Expenditures grew to $8.2 million in Q2 2026, from $5.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $13.1 million in Q2 2024 to a low of $4.3 million in Q3 2023.
• A 5-year average of $7.8 million and a median of $7.9 million in 2022 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures sank 62.18% — and 2024, when it jumped 152.67%.
• Tracing NEO's Capital Expenditures over 5 years: stood at $4.5 million in 2022, then surged by 55.65% to $7.1 million in 2023, then jumped by 64.36% to $11.6 million in 2024, then tumbled by 32.14% to $7.9 million in 2025, then increased by 4.42% to $8.2 million in 2026.
• The last three Capital Expenditures figures came in at $8.2 million (Q2 2026), $5.0 million (Q1 2026), and $7.9 million (Q4 2025), per Business Quant data.